Select a medication above to begin.
Tamiflu
oseltamivir
Adult Dosing .
Dosage forms: CAP: 30 mg, 75 mg; SUSP: 6 mg per mL
Special Note
- [www.cdc.gov/flu]
- Info: >98% of currently circulating influenza virus in US is oseltamivir-susceptible
influenza A and B (seasonal flu) tx, uncomplicated
- [non-pregnant pts]
- Dose: 75 mg PO bid x5 days; Start: w/in 48h of sx onset; Info: may consider incr. to 150 mg PO bid if hospitalized w/ severe dz or immunocompromised; may extend tx if immunocompromised
- [pregnant pts]
- Dose: 75 mg PO bid x5 days; Start: w/in 48h of sx onset; Info: may consider higher dose at 105 mg PO bid; may consider incr. to 150 mg PO bid if hospitalized w/ severe dz or immunocompromised; may extend tx if immunocompromised
influenza A and B (seasonal flu) prophylaxis
- [75 mg PO qd x7 days after last known exposure]
- Start: w/in 48h of exposure; Info: give for at least 14 days and x7 days after last known case for institutional setting outbreaks; consider pre-exposure prophylaxis if very high risk for complications and cannot receive influenza vaccine, start when influenza activity detected in community and continue for duration of influenza activity
renal dosing
- [treatment]
- CrCl 31-60: 30 mg bid x5 days; CrCl 11-30: 30 mg qd x5 days; CrCl <10: avoid use
- HD: 30 mg x1 then 30 mg 3x/wk after dialysis x5 days; consider supplement if next maint. dose not due right after dialysis; PD: 30 mg x1; supplement not defined
- [prophylaxis]
- CrCl 31-60: 30 mg qd; CrCl 11-30: 30 mg q48h; CrCl <10: avoid use
- HD: 30 mg x1 then 30 mg after every other dialysis; consider supplement if next maint. dose not due right after dialysis; PD: 30 mg x1 then 30 mg qwk; supplement not defined
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined
Peds Dosing .
- Dosage forms: CAP: 30 mg, 45 mg, 75 mg; SUSP: 6 mg per mL
Special Note
- [www.cdc.gov/flu]
- Info: >98% of currently circulating influenza virus in US is oseltamivir-susceptible
influenza A and B (seasonal flu) tx, uncomplicated
- [preterm infants, <38 wk postmenstrual age (off-label)]
- Dose: 1 mg/kg/dose PO bid x5 days; Start: w/in 48h of sx onset; Info: may extend tx if immunocompromised
- [preterm infants, 38-40 wk postmenstrual age (off-label)]
- Dose: 1.5 mg/kg/dose PO bid x5 days; Start: w/in 48h of sx onset; Info: may extend tx if immunocompromised
- [preterm infants, >40 wk postmenstrual age (off-label)]
- Dose: 3 mg/kg/dose PO bid x5 days; Start: w/in 48h of sx onset; Info: may extend tx if immunocompromised
- [<14 days old (off-label)]
- Dose: 3 mg/kg/dose PO bid x5 days; Start: w/in 48h of sx onset; Info: for full-term infants; may extend tx if immunocompromised
- [14 days old-11 mo]
- Dose: 3 mg/kg/dose PO bid x5 days; Start: w/in 48h of sx onset; Info: for full-term infants; may extend tx if immunocompromised
- [1-12 yo, <15 kg]
- Dose: 30 mg PO bid x5 days; Start: w/in 48h of sx onset; Info: may extend tx if immunocompromised
- [1-12 yo, 15-23 kg]
- Dose: 45 mg PO bid x5 days; Start: w/in 48h of sx onset; Info: may extend tx if immunocompromised
- [1-12 yo, 23.1-40 kg]
- Dose: 60 mg PO bid x5 days; Start: w/in 48h of sx onset; Info: may extend tx if immunocompromised
- [1-12 yo, >40 kg]
- Dose: 75 mg PO bid x5 days; Start: w/in 48h of sx onset; Info: may consider incr. to 150 mg PO bid if hospitalized w/ severe dz or immunocompromised; may extend tx if immunocompromised
- [13 yo and older, non-pregnant pts]
- Dose: 75 mg PO bid x5 days; Start: w/in 48h of sx onset; Info: may consider incr. to 150 mg PO bid if hospitalized w/ severe dz or immunocompromised; may extend tx if immunocompromised
- [13 yo and older, pregnant pts]
- Dose: 75 mg PO bid x5 days; Start: w/in 48h of sx onset; Info: may consider higher dose at 105 mg PO bid; may consider incr. to 150 mg PO bid if hospitalized w/ severe dz or immunocompromised; may extend tx if immunocompromised
influenza A and B (seasonal flu) prophylaxis
- [3-11 mo (off-label)]
- Dose: 3 mg/kg/dose PO qd x7 days after last known exposure; Start: w/in 48h of exposure; Info: for full-term infants; give for at least 14 days and x7 days after last known case for institutional setting outbreaks; consider pre-exposure prophylaxis if very high risk for complications and cannot receive influenza vaccine, start when influenza activity detected in community and continue for duration of influenza activity; not recommended in <3 mo unless situation critical
- [1-12 yo, <15 kg]
- Dose: 30 mg PO qd x7 days after last known exposure; Start: w/in 48h of exposure; Info: give for at least 14 days and x7 days after last known case for institutional setting outbreaks; consider pre-exposure prophylaxis if very high risk for complications and cannot receive influenza vaccine, start when influenza activity detected in community and continue for duration of influenza activity
- [1-12 yo, 15-23 kg]
- Dose: 45 mg PO qd x7 days after last known exposure; Start: w/in 48h of exposure; Info: give for at least 14 days and x7 days after last known case for institutional setting outbreaks; consider pre-exposure prophylaxis if very high risk for complications and cannot receive influenza vaccine, start when influenza activity detected in community and continue for duration of influenza activity
- [1-12 yo, 23.1-40 kg]
- Dose: 60 mg PO qd x7 days after last known exposure; Start: w/in 48h of exposure; Info: give for at least 14 days and x7 days after last known case for institutional setting outbreaks; consider pre-exposure prophylaxis if very high risk for complications and cannot receive influenza vaccine, start when influenza activity detected in community and continue for duration of influenza activity
- [1-12 yo, >40 kg]
- Dose: 75 mg PO qd x7 days after last known exposure; Start: w/in 48h of exposure; Info: give for at least 14 days and x7 days after last known case for institutional setting outbreaks; consider pre-exposure prophylaxis if very high risk for complications and cannot receive influenza vaccine, start when influenza activity detected in community and continue for duration of influenza activity
- [13 yo and older]
- Dose: 75 mg PO qd x7 days after last known exposure; Start: w/in 48h of exposure; Info: give for at least 14 days and x7 days after last known case for institutional setting outbreaks; consider pre-exposure prophylaxis if very high risk for complications and cannot receive influenza vaccine, start when influenza activity detected in community and continue for duration of influenza activity
renal dosing
- [treatment, <1 yo]
- renal impairment: not defined
- HD/PD: not defined
- [treatment, 1 yo and older]
- CrCl 31-60: give 50% usual dose q12h; CrCl 11-30: give 50% usual dose q24h; CrCl <10: not defined
- HD: 7.5 mg x1 after dialysis if wt <16 kg; 10 mg x1 after dialysis if wt 16-23 kg; 15 mg x1 after dialysis if wt 24-40 kg; 30 mg x1 then 30 mg 3x/wk after dialysis if wt >40 kg; consider supplement if next maint. dose not due right after dialysis; PD: give 50% usual dose x1; supplement not defined
- [prophylaxis]
- renal impairment: not defined, consider adult renal dosing for guidance
- HD/PD: not defined, consider adult renal dosing for guidance
hepatic dosing
- [see below]
- Child-Pugh Class A or B: no adjustment; Child-Pugh Class C: not defined